To determine the impact of β-catenin on NHERF1 expression, we used an integrated doxycycline (Dox)-inducible shRNA vector to silence β-catenin in two human cell lines that recapitulate the earliest events implicated in CRC (Ls174T have mutated β-catenin/KRAS genes and DLD-1 have mutated APC/KRAS genes) [14–16]. This evidence concerns the gene NHERF1 and colorectal carcinoma.